Please assess the completion status of the following clinical trial:

Trial Title: Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 20 - 40 years, inclusive~* Body mass index ≥ 25 kg/m2~* History of irregular menstrual cycles (fewer than 6 cycles in the past year)~* Clinical and/or biochemical androgen excess (Free androgen index\>3.85 and/or hirsuitism rating ≥8)~* Anovulatory menstrual cycles (determined during screening)~Exclusion Criteria:~* Ovulatory menstrual cycles (determined during screening by luteal phase serum progesterone \>3ng/mL)~* History or clinical appearance of cardiovascular disease, diabetes (Type 1 or Type 2) and any other significant reproductive, metabolic, hematologic, pulmonary, gastrointestinal, neurologic, immune, hepatic, renal, urologic disorders, or cancer.~* Hemoglobin, hematocrit, red blood cell count, or iron level below the lower limit of normal at the screening visit confirmed by a test repeated within two weeks~* Regular use of medications for weight control, glucose intolerance, thyroid disease~* Use of hormonal contraception containing medroxyprogesterone acetate (A 3 month washout period will be permitted for oral, vaginal and transdermal contraceptives).~Psychiatric and Behavioral Exclusion Criteria~* Smoking~* History of drug or alcohol abuse (up to 14 drinks a week are allowed) within the past two years~* History or presence of an eating disorder as determined by Interview for Diagnosis of Eating Disorders (IDED-IV)~* Beck Depression Index (BDI) score of ≥15 at screening or baseline~Other Exclusion Criteria~* Individuals who have lost more than 5kg (11lbs) in the past 6 months~* Individuals who are pregnant or breast-feeding or whom become pregnant during the study~* Individuals engaged in a regular program of physical fitness involving some heavy physical activity (e.g., jogging or riding fast on a bicycle for 30 minutes or more) at least five times per week over the past year~* Individuals who have metallic objects in their body~* Individuals who donated blood within 30 days prior to the date of randomization~* Individuals unwilling to be assigned at random to either one of the intervention groups~* Unwilling or unable to adhere to the rigors of the data collection (determined by food and activities diaries at screening, see below) and clinical evaluation schedule over the entire 24 week intervention period~* Individuals who plan to move out of the area within the next 12 months or plan to be out of the study area for more than 4 weeks in the next 12 months~* Individuals who reside too far from Pennington

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: EXPERIMENTAL): Subjects randomized to the metformin treatment group will receive 1000 mg extended release metformin hydrochloride tablets (Bristol Myers Squibb) twice per day with food approximately 8 hours apart.
- Dietary Restriction (Type: EXPERIMENTAL): Subjects randomized to the dietary restriction group (DR) will reduce their energy intake by 25% from their weight maintenance energy intake determined at baseline by doubly labeled water.There will be no gradual ramping of dietary restriction. The 25% energy reduction goal will apply from the first day of the intervention for a period of 24 weeks. Subjects will be asked to not modify their normal level of physical activity.
- Exercise (Type: EXPERIMENTAL): Subjects randomized to the exercise training group will complete a structured program of aerobic training 3 to 4 times per week and resistance exercises 2 times per week.
- Control (Type: NO_INTERVENTION): Subjects randomized to the no treatment control group will be asked to continue, as normal their usual dietary and exercise regimen. Subjects will be asked to not begin diet or exercise regimens through the 24-week study or to begin medical treatment for PCOS.

Based on this trial design, predict the completion outcome and termination type (if applicable).